{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:08:59Z","timestamp":1775560139605,"version":"3.50.1"},"reference-count":98,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Inflammatory bowel diseases (IBD), which enclose Crohn\u2019s disease (CD) and ulcerative colitis (UC), are chronic, relapsing inflammatory ailments. Their specific pathogenesis is not completely clarified, the worldwide incidence and prevalence of IBD has been steadily growing, and there is still not a definitive cure. The management of IBD has become more and more targeted, with specific immune mediators identified to be involved in its pathogenesis. Vedolizumab, a humanised monoclonal antibody binding specifically to the \u03b14\u03b27 integrin, is a gut-selective immunosuppressive biologic drug administered for both CD and UC. With the same indications as vedolizumab, ustekinumab is a fully human IgG1\u03ba monoclonal antibody binding with specificity to the shared p40 protein subunit of human cytokines interleukin (IL)-12 and IL-23. Several selective IL-23p19 monoclonal antibodies (risankizumab, mirikizumab, and guselkumab) have also revealed admirable efficacy and safety in IBD patients. Nutrition is a very important environmental factor associated with the onset and progression of IBD, and the Western diet is considered to contribute to the development of IBD. In this narrative review, our aim is to present an overview of the main results from recent clinical studies on IBD regarding diet, new drug treatments, and also vaccination.<\/jats:p>","DOI":"10.3389\/fphar.2024.1380878","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T09:45:03Z","timestamp":1725615903000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Recent clinical evidence on nutrition, novel pharmacotherapy, and vaccination in inflammatory bowel diseases"],"prefix":"10.3389","volume":"15","author":[{"given":"Theodora","family":"Gheonea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Bogdan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreea-Daniela","family":"Meca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ion","family":"Rogoveanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Oancea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"B1","volume-title":"Basic immunology: functions and disorders of the immune system","author":"Abbas","year":"2014"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/ecco-jcc\/jjac030","article-title":"Efficacy and safety of maintenance ustekinumab for ulcerative colitis through 3 Years: UNIFI long-term extension","volume":"16","author":"Abreu","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5582\/ddt.2019.01000","article-title":"Role of inulin as prebiotics on inflammatory bowel disease","volume":"13","author":"Akram","year":"2019","journal-title":"Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"651415","DOI":"10.3389\/fphar.2021.651415","article-title":"Novel and emerging therapies for inflammatory bowel disease","volume":"12","author":"Al-Bawardy","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1053\/j.gastro.2020.12.079","article-title":"Canadian association of Gastroenterology clinical practice guideline for immunizations in patients with inflammatory bowel disease (IBD)-Part 1: live vaccines","volume":"161","author":"Benchimol","year":"2021","journal-title":"Gastroenterology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","article-title":"Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders","volume":"3","author":"Benson","year":"2011","journal-title":"MAbs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.33590\/emjgastroenterol\/20-00166","article-title":"An overview of novel and emerging therapies for inflammatory bowel disease EMJ gastroenterol","volume":"9","author":"Bhattacharya","year":"2020"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1016\/j.vaccine.2023.05.012","article-title":"Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease","volume":"41","author":"Bordalo Ferreira","year":"2023","journal-title":"Vaccine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.3390\/biomedicines11082249","article-title":"Inflammatory bowel disease: emerging therapies and future treatment strategies","volume":"11","author":"Bretto","year":"2023","journal-title":"Biomedicines"},{"key":"B11","first-page":"97","article-title":"Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue","volume":"151","author":"Briskin","year":"1997","journal-title":"Am. J. Pathol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"44482","DOI":"10.1038\/srep44482","article-title":"Nutritional control of IL-23\/Th17-mediated autoimmune disease through HO-1\/STAT3 activation","volume":"7","author":"Br\u00fcck","year":"2017","journal-title":"Sci. Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/ibd\/izz164","article-title":"Immunogenicity of high dose influenza vaccine for patients with inflammatory bowel disease on anti-TNF monotherapy: a randomized clinical trial","volume":"26","author":"Caldera","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3390\/nu13041067","article-title":"Food and food groups in inflammatory bowel disease (IBD): the design of the groningen anti-inflammatory diet (GrAID)","volume":"13","author":"Campmans-Kuijpers","year":"2021","journal-title":"Nutrients"},{"key":"B15","unstructured":"Data and statistics2023"},{"key":"B16","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1053\/j.gastro.2016.10.004","article-title":"Complementary and alternative Medicines used by patients with inflammatory bowel diseases","volume":"152","author":"Cheifetz","year":"2017","journal-title":"Gastroenterology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"761981","DOI":"10.3389\/fimmu.2021.761981","article-title":"Interaction between commensal bacteria, immune response and the intestinal barrier in inflammatory bowel disease","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.3748\/wjg.v16.i20.2484","article-title":"Lifestyle-related disease in Crohn\u2019s disease: relapse prevention by a semi-vegetarian diet","volume":"16","author":"Chiba","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s40262-023-01281-z","article-title":"Mirikizumab pharmacokinetics in patients with moderately to severely active ulcerative colitis: results from phase III LUCENT studies","volume":"62","author":"Chua","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s11894-023-00874-9","article-title":"Indications and safety of newer IBD treatments in the older patient","volume":"25","author":"Clement","year":"2023","journal-title":"Curr. Gastroenterol. Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1016\/j.cgh.2021.03.028","article-title":"Predictors and outcomes of ustekinumab dose intensification in ulcerative colitis: a multicenter cohort study","volume":"20","author":"Dalal","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B22","volume-title":"Roitt\u2019s essential immunology","author":"Delves","year":"2017"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1007\/s12325-023-02546-6","article-title":"Matching-adjusted indirect comparison between risankizumab and ustekinumab for induction and maintenance treatment of moderately to severely active crohn's disease","volume":"40","author":"Dubinsky","year":"","journal-title":"Adv. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"otac044","DOI":"10.1093\/crocol\/otac044","article-title":"Clinical effect of mirikizumab treatment on bowel urgency in patients with moderately to severely active ulcerative colitis and the clinical relevance of bowel urgency improvement for disease remission","volume":"360","author":"Dubinsky","year":"","journal-title":"Crohns Colitis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e001115","DOI":"10.1136\/bmjgast-2023-001115","article-title":"Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis","volume":"10","author":"Dubinsky","year":"","journal-title":"BMJ Open Gastroenterol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"otac016","DOI":"10.1093\/crocol\/otac016","article-title":"Impact of bowel urgency on quality of life and clinical outcomes in patients with ulcerative colitis","volume":"360","author":"Dubinsky","year":"","journal-title":"Crohns Colitis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"6966","DOI":"10.3390\/ijms23136966","article-title":"Inflammatory bowel disease treatments and predictive biomarkers of therapeutic response","volume":"23","author":"Elhag","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B28","volume-title":"Product information","year":""},{"key":"B98","volume-title":"Product information","year":""},{"key":"B29","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e13139","DOI":"10.1111\/sji.13139","article-title":"B cell class switching in intestinal immunity in health and disease","volume":"95","author":"Fleming","year":"2022","journal-title":"Scand. J. Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1016\/j.vaccine.2016.04.023","article-title":"The generation of memory B cells is maintained, but the antibody response is not, in the elderly after repeated influenza immunizations","volume":"34","author":"Frasca","year":"2016","journal-title":"Vaccine"},{"key":"B33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1620\/tjem.255.57","article-title":"Ustekinumab as the first biological agent for crohn's disease in a 10-year-old girl","volume":"255","author":"Fujita","year":"2021","journal-title":"Tohoku J. Exp. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"5596","DOI":"10.7150\/thno.73650","article-title":"Turmeric-derived nanovesicles as novel nanobiologics for targeted therapy of ulcerative colitis","volume":"12","author":"Gao","year":"2022","journal-title":"Theranostics"},{"key":"B35","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3390\/vaccines10020297","article-title":"Response to vaccines in patients with immune-mediated inflammatory diseases: a narrative review","volume":"10","author":"Garcill\u00e1n","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","year":"2020","journal-title":"Lancet Gastroenterology Hepatology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.autrev.2013.06.004","article-title":"Innate and adaptive immunity in inflammatory bowel disease","volume":"13","author":"Geremia","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.3390\/nu14204261","article-title":"Dietary interventions in inflammatory bowel disease","volume":"14","author":"Godala","year":"2022","journal-title":"Nutrients"},{"key":"B39","doi-asserted-by":"publisher","first-page":"ii73","DOI":"10.1093\/ecco-jcc\/jjab190","article-title":"Personalised medicine with IL-23 blockers: myth or reality?","volume":"16","author":"Gottlieb","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/14712598.2020.1697227","article-title":"Anti-interleukin-23 agents for the treatment of ulcerative colitis","volume":"20","author":"Han\u017eel","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"otaa082","DOI":"10.1093\/crocol\/otaa082","article-title":"The immunogenicity of the influenza, pneumococcal, and hepatitis B vaccines in patients with inflammatory bowel disease treated with vedolizumab","volume":"360","author":"Harrington","year":"2020","journal-title":"Crohns Colitis"},{"key":"B42","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/DDDT.S379446","article-title":"Clinical evaluation of risankizumab in the treatment of adults with moderately to severely active crohn's disease: patient selection and reported outcomes","volume":"17","author":"Horst","year":"2023","journal-title":"Drug Des. Devel Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00535-022-01953-w","article-title":"Expert consensus on vaccination in patients with inflammatory bowel disease in Japan","volume":"58","author":"Ishige","year":"2023","journal-title":"J. Gastroenterol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"630","DOI":"10.14309\/ajg.0000000000000197","article-title":"Impact of obesity on disease activity and patient-reported outcomes measurement information System (PROMIS) in inflammatory bowel diseases","volume":"114","author":"Jain","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/978-3-030-00710-2_14","article-title":"Vaccines","volume":"14","author":"Jiskoot","year":"2019","journal-title":"Pharm. Biotechnol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1053\/j.gastro.2021.04.034","article-title":"Canadian association of Gastroenterology clinical practice guideline for immunizations in patients with inflammatory bowel disease (IBD)-Part 2: inactivated vaccines","volume":"161","author":"Jones","year":"2021","journal-title":"Gastroenterology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"5464","DOI":"10.1016\/j.vaccine.2015.08.011","article-title":"Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease","volume":"33","author":"Kants\u00f8","year":"2015","journal-title":"Vaccine"},{"key":"B48","doi-asserted-by":"publisher","first-page":"462","DOI":"10.14309\/ajg.0000000000001619","article-title":"Factors affecting initial humoral immune response to SARS-cov-2 vaccines among patients with inflammatory bowel diseases","volume":"117","author":"Kappelman","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s40265-023-01909-1","article-title":"Mirikizumab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"B50","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"B51","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/15548627.2019.1635384","article-title":"New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD","volume":"16","author":"Larabi","year":"2020","journal-title":"Autophagy"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/ecco-jcc\/jjv152","article-title":"Immunogenicity and safety of influenza vaccine in inflammatory bowel disease patients treated or not with immunomodulators and\/or biologics: a two-year prospective study","volume":"9","author":"Launay","year":"2015","journal-title":"J. Crohns Colitis"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41467-022-28517-z","article-title":"Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab","volume":"13","author":"Lin","year":"2022","journal-title":"Nat. Commun."},{"key":"B54","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/ecco-jcc\/jjw177","article-title":"Long-term efficacy of vedolizumab for ulcerative colitis","volume":"11","author":"Loftus","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/apt.16060","article-title":"Long-term safety of vedolizumab for inflammatory bowel disease","volume":"52","author":"Loftus","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.2147\/JIR.S353038","article-title":"Immunology of inflammatory bowel disease: molecular mechanisms and therapeutics","volume":"15","author":"Lu","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"612830","DOI":"10.3389\/fcell.2021.612830","article-title":"Vedolizumab: potential mechanisms of action for reducing pathological inflammation in inflammatory bowel diseases","volume":"9","author":"Luzentales-Simpson","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.3748\/wjg.v30.i12.1644","article-title":"Interaction between diet and genetics in patients with inflammatory bowel disease","volume":"30","author":"Magro","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"11273","DOI":"10.3748\/wjg.v21.i40.11273","article-title":"Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease","volume":"21","author":"Mar\u00edn","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000507782","article-title":"Emerging treatment options in inflammatory bowel disease: Janus kinases, stem cells, and more","volume":"101","author":"Misselwitz","year":"2020","journal-title":"Digestion"},{"key":"B61","doi-asserted-by":"publisher","first-page":"n1554","DOI":"10.1136\/bmj.n1554","article-title":"Association of ultra\u2010processed food intake with risk of inflammatory bowel disease: prospective cohort study","volume":"374","author":"Narula","year":"2021","journal-title":"BMJ"},{"key":"B62","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.cgh.2018.07.004","article-title":"Obesity is independently associated with higher annual burden and costs of hospitalization in patients with inflammatory bowel diseases","volume":"17","author":"Nguyen","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"611256","DOI":"10.3389\/fimmu.2021.611256","article-title":"The IL23-IL17 immune Axis in the treatment of ulcerative colitis: successes, defeats, and ongoing challenges","volume":"12","author":"Noviello","year":"2021","journal-title":"Front. Immunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jaci.2010.08.048","article-title":"\u03b14\u03b27 Integrin is essential for contact hypersensitivity by regulating migration of T cells to skin","volume":"126","author":"Ohmatsu","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3390\/cells8070659","article-title":"Inflammatory bowel disease: a stressed Gut\/Feeling","volume":"8","author":"Oligschlaeger","year":"2019","journal-title":"Cells"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.14309\/ajg.0000000000001773","article-title":"An objective comparison of vedolizumab and ustekinumab effectiveness in crohn's disease patients' failure to TNF-alpha inhibitors","volume":"117","author":"Onali","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","article-title":"Targeting integrin pathways: mechanisms and advances in therapy","volume":"8","author":"Pang","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"B68","doi-asserted-by":"publisher","first-page":"ii64","DOI":"10.1093\/ecco-jcc\/jjab185","article-title":"Blockade of IL-23: what is in the pipeline?","volume":"16","author":"Parigi","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1053\/j.gastro.2023.08.038","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction study","volume":"165","author":"Peyrin-Biroulet","year":"2023","journal-title":"Gastroenterology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1053\/j.gastro.2021.06.015","article-title":"Histologic outcomes with vedolizumab versus adalimumab in ulcerative colitis: results from an efficacy and safety study of vedolizumab intravenous compared to adalimumab subcutaneous in participants with ulcerative colitis (VARSITY)","volume":"161","author":"Peyrin-Biroulet","year":"2021","journal-title":"Gastroenterology"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.14309\/ajg.0000000000000289","article-title":"High immunogenicity of the pneumococcal conjugated vaccine in immunocompromised adults with inflammatory bowel disease","volume":"114","author":"Pittet","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"70","DOI":"10.18773\/austprescr.2020.015","article-title":"Risankizumab for psoriasis","volume":"43","year":"2020","journal-title":"Aust. Prescr."},{"key":"B73","unstructured":"Therapeutic protocols2017"},{"key":"B74","unstructured":"List of approved therapeutic protocols by ministerial order2023"},{"key":"B75","unstructured":"List of therapeutic protocols2021"},{"key":"B76","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3390\/nu14040751","article-title":"Nutrition in patients with inflammatory bowel diseases: a narrative review","volume":"14","author":"Roncoroni","year":"2022","journal-title":"Nutrients"},{"key":"B77","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3389\/fphar.2019.00872","article-title":"Mini review: new treatments in psoriatic arthritis. Focus on the IL-23\/17 Axis","volume":"10","author":"Sakkas","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"GALAXI-1 investigators. Guselkumab for the treatment of crohn's disease: induction results from the phase 2 GALAXI-1 study","volume":"162","author":"Sandborn","year":"","journal-title":"Gastroenterology"},{"key":"B80","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-year efficacy and safety of ustekinumab treatment in crohn's disease: the IM-UNITI trial","volume":"20","author":"Sandborn","year":"","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.tins.2016.09.002","article-title":"Psychobiotics and the manipulation of bacteria-gut-brain signals","volume":"39","author":"Sarkar","year":"2016","journal-title":"Trends Neurosci."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1093\/ibd\/izx101","article-title":"Immunogenicity of quadrivalent influenza vaccine for patients with inflammatory bowel disease undergoing immunosuppressive therapy","volume":"24","author":"Shirai","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"956","DOI":"10.3389\/fimmu.2019.00956","article-title":"Role of multivalency and antigenic threshold in generating protective antibody responses","volume":"10","author":"Slifka","year":"2019","journal-title":"Front. Immunol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3390\/nu15010240","article-title":"Nutritional status indicators as a predictor of achieving remission at week 14 during vedolizumab therapy in patients with ulcerative colitis: a pilot study","volume":"15","author":"Sobolewska-W\u0142odarczyk","year":"2023","journal-title":"Nutrients"},{"key":"B86","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1124\/jpet.122.001512","article-title":"Generation and characterization of mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of IL-23","volume":"387","author":"Steere","year":"2023","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B87","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000506364","article-title":"Treatment algorithms for crohn's disease","volume":"101","author":"Sulz","year":"2020","journal-title":"Digestion"},{"key":"B88","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/MPG.0000000000000103","article-title":"Nutritional therapy in pediatric Crohn disease: the specific carbohydrate diet","volume":"58","author":"Suskind","year":"2014","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"B89","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/ecco-jcc\/jjz051","article-title":"European Crohn\u2019s and colitis organisation topical review on complementary medicine and psychotherapy in inflammatory bowel disease","volume":"13","author":"Torres","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"B90","unstructured":"2024"},{"key":"B91","doi-asserted-by":"publisher","first-page":"ii20","DOI":"10.1093\/ecco-jcc\/jjac023","article-title":"What can IBD specialists learn from IL-23 trials in dermatology?","volume":"16","author":"Valenti","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"B92","doi-asserted-by":"publisher","first-page":"S018","DOI":"10.1093\/ecco-jcc\/jjy222.025","article-title":"OP26 Long-term safety of vedolizumab in ulcerative colitis and Crohn\u2019s disease: final results from the GEMINI LTS study","volume":"13","author":"Vermeire","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"B93","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","article-title":"Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active crohn's disease: results from the VISIBLE 2 randomised trial","volume":"16","author":"Vermeire","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"B94","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/ecco-jcc\/jjw176","article-title":"Long-term efficacy of vedolizumab for crohn's disease","volume":"11","author":"Vermeire","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"B95","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3748\/wjg.v20.i1.6","article-title":"Immunopathology of inflammatory bowel disease","volume":"20","author":"Wallace","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"880190","DOI":"10.3389\/fimmu.2022.880190","article-title":"Differences in SARS-CoV-2 vaccine response dynamics between class-I- and class-II-specific T-cell receptors in inflammatory bowel disease","volume":"13","author":"Xu","year":"2022","journal-title":"Front. Immunol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"e000844","DOI":"10.1128\/CMR.00084-18","article-title":"Factors that influence the immune response to vaccination","volume":"32","author":"Zimmermann","year":"2019","journal-title":"Clin. Microbiol. Rev."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1380878\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T09:45:12Z","timestamp":1725615912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1380878\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":98,"alternative-id":["10.3389\/fphar.2024.1380878"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1380878","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]},"article-number":"1380878"}}